COMMUNIQUÉS West-GlobeNewswire

23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
04/06/2024
Study aims to fill research gap and empower people through access to information about their health SUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic [...]
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product
04/06/2024
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today [...]
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
04/06/2024
Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early [...]
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
04/06/2024
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hours High treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score compared to placebo ZUG [...]
The Ensign Group Adds Another Skilled Nursing Facility in Colorado
04/06/2024
SAN JUAN CAPISTRANO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
The Ensign Group Acquires Skilled Nursing Facility in Arizona
04/06/2024
SAN JUAN CAPISTRANO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
ExeVir Bio Announces Exceptional Virus Neutralization Potency of its Variant-proof XVR013m Antibody Against the SARS-CoV-2 Variant JN.1
04/06/2024
Developed to provide protection for millions of immunocompromised and elderly individuals who are most vulnerable to COVID-19 GHENT, Belgium, June 04, 2024 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing [...]
BioVersys Awarded Non-Dilutive Funding From CF AMR Syndicate Collaborative Discovery Programme
04/06/2024
BASEL, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- CF AMR Syndicate awarded BioVersys up to £ 500,000 to support project addressing resistant non-tubercular mycobacteria (NTM) lung infections in people with cystic [...]
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
04/06/2024
June 4, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
Les maladies allergiques coûtent directement entre 1 800 et 6 600 euros par patient et par an
04/06/2024
Le registre HEAD, qui compte près de 800 patients, permet d’évaluer l’impact économique et social des allergies au niveau européen VALENCE, Espagne, 04 juin 2024 (GLOBE NEWSWIRE) -- Les maladies allergiques coûtent [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/06/2024
NEW YORK & SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule [...]
Nyxoah to Participate in the Jefferies Global Healthcare Conference
03/06/2024
Nyxoah to Participate in the Jefferies Global Healthcare Conference Mont-Saint-Guibert, Belgium – June 3, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical [...]
Nyxoah Participera à la Conférence Jefferies Global Healthcare
03/06/2024
Nyxoah Participera à la Conférence Jefferies Global Healthcare Mont-Saint-Guibert, Belgique – 3 juin 2024, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») opère dans le [...]
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
03/06/2024
Call scheduled for Tuesday, June 4, 2024 at 8:30 a.m. ET BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement- [...]
American Oncology Network Appoints David Afshar as Chief Financial and Operating Officer
03/06/2024
Veteran Financial Leader David Afshar will lead the company’s financial and operating strategy. FORT MYERS, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC), one of the nation’s [...]
Arvinas to Participate in Upcoming Investor Conferences
03/06/2024
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that [...]
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
03/06/2024
SAN DIEGO and TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral [...]
First of Its Kind Beverage that Reduces Blood Alcohol Content Safety Shot Partners with Mr. Checkout to Expand Presence with Independent Retailers Nationwide
03/06/2024
The Partnership Aims to Provide More Access For Consumers In Diversified Retail Locations JUPITER, FL, June 03, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (the “Company), announced today its strategic [...]
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
03/06/2024
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination with standard- [...]

Pages